SG11201700849XA - Novel formulations of a bruton's tyrosine kinase inhibitor - Google Patents

Novel formulations of a bruton's tyrosine kinase inhibitor

Info

Publication number
SG11201700849XA
SG11201700849XA SG11201700849XA SG11201700849XA SG11201700849XA SG 11201700849X A SG11201700849X A SG 11201700849XA SG 11201700849X A SG11201700849X A SG 11201700849XA SG 11201700849X A SG11201700849X A SG 11201700849XA SG 11201700849X A SG11201700849X A SG 11201700849XA
Authority
SG
Singapore
Prior art keywords
bruton
tyrosine kinase
kinase inhibitor
novel formulations
formulations
Prior art date
Application number
SG11201700849XA
Other languages
English (en)
Inventor
Cassandra Shu
Harisha Atluri
Robert Kuehl
Pearl Shwe-Cho Tay
Ryan Mitchell Minikis
James Francis Hulvat
Alexander Jacob Mcvey
Ching Wah Chong
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of SG11201700849XA publication Critical patent/SG11201700849XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
SG11201700849XA 2014-08-07 2015-08-07 Novel formulations of a bruton's tyrosine kinase inhibitor SG11201700849XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462034353P 2014-08-07 2014-08-07
PCT/US2015/044258 WO2016022942A1 (en) 2014-08-07 2015-08-07 Novel formulations of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
SG11201700849XA true SG11201700849XA (en) 2017-03-30

Family

ID=55264642

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201700849XA SG11201700849XA (en) 2014-08-07 2015-08-07 Novel formulations of a bruton's tyrosine kinase inhibitor

Country Status (13)

Country Link
US (4) US9545407B2 (ko)
EP (1) EP3193877A4 (ko)
JP (1) JP2017523206A (ko)
KR (1) KR20170033358A (ko)
CN (1) CN106573002A (ko)
AU (1) AU2015300798A1 (ko)
BR (1) BR112017002231A2 (ko)
CA (1) CA2955747A1 (ko)
IL (1) IL250085A0 (ko)
MX (1) MX2017001671A (ko)
RU (1) RU2017106795A (ko)
SG (1) SG11201700849XA (ko)
WO (1) WO2016022942A1 (ko)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
WO2016022942A1 (en) * 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
SG11201707122QA (en) 2015-03-03 2017-09-28 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
EP3280446A1 (en) * 2015-04-06 2018-02-14 Janssen Pharmaceutica, N.V. Compositions containing ibrutinib
EP3405177A1 (en) * 2016-01-19 2018-11-28 Janssen Pharmaceutica NV Formulations/compositions comprising a btk inhibitor
AU2018257901A1 (en) * 2017-04-24 2019-11-14 Samus Therapeutics, Inc. Hsp90 inhibitor oral formulations and related methods
CN107014943B (zh) * 2017-06-07 2018-08-21 福建省微生物研究所 一种依鲁替尼对映异构体的检测方法
DK3644970T3 (da) * 2017-06-30 2022-03-14 Acrotech Biopharma Llc Nye orale formuleringer af belinostat
JP7190452B2 (ja) * 2017-07-04 2022-12-15 ジエンス ヘンルイ メデイシンカンパニー リミテッド 医薬組成物及びその製造方法
CN110913840A (zh) * 2017-08-11 2020-03-24 默克专利股份公司 包含3-氟-4-[7-甲氧基-3-甲基-8-(1-甲基-1H-吡唑-4-基)-2-氧代-2,3-二氢-咪唑并[4,5-c]喹啉-1-基]-苄腈的药物制剂
CN111565721A (zh) 2017-09-19 2020-08-21 西普拉有限公司 具有增强的生物利用度的包含依鲁替尼和生物碱的组合物
WO2019070698A1 (en) 2017-10-02 2019-04-11 Johnson Matthey Public Limited Company NEW FORMS OF IBRUTINIB
CN111212644B (zh) * 2017-11-10 2021-01-15 苏州信诺维医药科技有限公司 作为btk抑制剂的5-氨基吡唑甲酰胺化合物的无定型固体分散体
CZ2017787A3 (cs) * 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
WO2019142207A1 (en) * 2018-01-20 2019-07-25 Natco Pharma Limited Pharmaceutical compositions comprising ibrutinib
CN111818915B (zh) 2018-01-31 2024-05-24 德西费拉制药有限责任公司 治疗胃肠道间质瘤的组合疗法
WO2019195827A1 (en) 2018-04-06 2019-10-10 Johnson Matthey Public Limited Company Novel form of ibrutinib
EP3787751A1 (en) 2018-05-03 2021-03-10 Juno Therapeutics, Inc. Combination therapy of a chimeric antigen receptor (car) t cell therapy and a kinase inhibitor
MA52874A (fr) 2018-06-15 2021-04-21 Janssen Pharmaceutica Nv Formulations/compositions comprenant de l'ibrutinib
US20210330643A1 (en) * 2018-07-31 2021-10-28 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
AU2020329956B2 (en) 2019-08-12 2023-11-16 Deciphera Pharmaceuticals, Llc. Ripretinib for treating gastrointestinal stromal tumors
WO2021056048A1 (en) * 2019-09-23 2021-04-01 Bionomics Limited Therapeutic formulations and uses thereof
JP2023509628A (ja) 2019-12-30 2023-03-09 デシフェラ・ファーマシューティカルズ，エルエルシー １－（４－ブロモ－５－（１－エチル－７－（メチルアミノ）－２－オキソ－１，２－ジヒドロ－１，６－ナフチリジン－３－イル）－２－フルオロフェニル）－３－フェニル尿素の組成物
BR112022013109A2 (pt) * 2019-12-30 2022-09-06 Deciphera Pharmaceuticals Llc Formulações de inibidor de quinase amorfo e métodos de uso das mesmas
EP4142699A1 (en) * 2020-04-30 2023-03-08 Nanocopoeia LLC Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN111617028A (zh) * 2020-07-14 2020-09-04 扬子江药业集团江苏紫龙药业有限公司 一种含伊布替尼的口服制剂及制备方法
EP4281047A1 (en) * 2021-01-21 2023-11-29 XSpray Pharma AB (publ) Fast dissolving pharmaceutical compositions of dasatinib
WO2022187822A1 (en) * 2021-03-03 2022-09-09 Oakwood Laboratories, Llc Microsphere formulations comprising btk inhibitors and methods for making and using the same
CN113509443B (zh) * 2021-07-14 2023-04-11 药源生物科技（启东）有限公司 一种含soluplus的固分体及其制备方法
WO2023104808A1 (en) * 2021-12-10 2023-06-15 Synthon B.V. Pharmaceutical composition comprising ibrutinib
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
CN115054603A (zh) * 2022-06-20 2022-09-16 上海宣泰医药科技股份有限公司 依鲁替尼药物组合物及其制备方法和药物制剂

Family Cites Families (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3303707A1 (de) 1983-02-04 1984-08-09 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur spaltung von organosiloxanen und dessen produkte und anwendungen
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
JPH01167840A (ja) 1987-12-24 1989-07-03 Konica Corp 新規な写真用シアンカプラー
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9226855D0 (en) 1992-12-23 1993-02-17 Erba Carlo Spa Vinylene-azaindole derivatives and process for their preparation
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
US5593997A (en) 1995-05-23 1997-01-14 Pfizer Inc. 4-aminopyrazolo(3-,4-D)pyrimidine and 4-aminopyrazolo-(3,4-D)pyridine tyrosine kinase inhibitors
CH690773A5 (de) 1996-02-01 2001-01-15 Novartis Ag Pyrrolo(2,3-d)pyrimide und ihre Verwendung.
AU3176297A (en) 1996-06-25 1998-01-14 Novartis Ag Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof
DE69815317T2 (de) 1997-03-19 2005-04-07 Abbott Gmbh & Co. Kg Pyrrolo[2,3-d]pyrimidine und ihre verwendung als tyrosinkinase-inhibitoren
ES2287971T3 (es) * 1997-08-11 2007-12-16 Pfizer Products Inc. Dispersiones farmaceuticas solidas con biodisponibilidad incrementada.
ES2185238T3 (es) * 1997-12-31 2003-04-16 Choongwae Pharma Corp Preparado oral de itraconazol y su procedimiento de preparacion.
IL139080A0 (en) 1998-04-17 2001-11-25 Parker Hughes Inst Btx inhibitors and methods for their indentification and use
US6303652B1 (en) 1998-08-21 2001-10-16 Hughes Institute BTK inhibitors and methods for their identification and use
US6998233B2 (en) 1998-06-26 2006-02-14 Sunesis Pharmaceuticals, Inc. Methods for ligand discovery
US20050287596A9 (en) 1998-06-26 2005-12-29 Braisted Andrew C Novel ligands and libraries of ligands
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
UA74141C2 (uk) 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
ES2307482T3 (es) * 1999-02-10 2008-12-01 Pfizer Products Inc. Dispersiones farmaceuticas solidas.
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
CZ2002936A3 (cs) 1999-09-17 2002-10-16 Abbott Gmbh & Co. Kg Pyrazolopyrimidiny jako terapeutické prostředky
MXPA02003364A (es) 1999-10-06 2002-08-23 Boehringer Ingelheim Pharma Compuestos heterociclicos utiles como inhibidores de las cinasas de tirosina.
US6506769B2 (en) 1999-10-06 2003-01-14 Boehringer Ingelheim Pharmaceuticals, Inc. Heterocyclic compounds useful as inhibitors of tyrosine kinases
WO2001041754A2 (en) 1999-11-30 2001-06-14 Parker Hughes Institute Inhibitors of collagen-induced platelet aggregation
IL150059A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Novel heterocycles
GB0005345D0 (en) 2000-03-06 2000-04-26 Mathilda & Terence Kennedy Ins Methods of treating sepsis septic shock and inflammation
GB0108903D0 (en) 2000-10-05 2001-05-30 Aventis Pharm Prod Inc Novel crystalline forms of a factor Xa inhibitor
HUP0303656A3 (en) 2000-10-23 2006-03-28 Bristol Myers Squibb Co Modulators of bruton's tyrosine kinase, their identification and use
WO2002045684A2 (en) 2000-12-06 2002-06-13 Pharmacia Corporation Rapidly dispersing pharmaceutical composition comprising effervescent agents
DE60206889T2 (de) * 2001-02-27 2006-07-27 Astrazeneca Ab Pharmazeutische formulierung enthaltend bicalutamid
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
US8306897B2 (en) 2001-05-04 2012-11-06 Stockshield, Inc. Method and system for insuring against investment loss
WO2003000187A2 (en) 2001-06-21 2003-01-03 Ariad Pharmaceuticals, Inc. Novel pyrazolo-and pyrrolo-pyrimidines and uses thereof
CN1523991A (zh) 2001-08-10 2004-08-25 ��˹��ŵ�� 单独的c-Src抑制剂或其与STI571的组合用于治疗白血病的用途
US20030118078A1 (en) 2001-08-10 2003-06-26 Carlson Eric D. Apparatuses and methods for creating and testing pre-formulations and systems for same
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
MXPA04004814A (es) 2001-11-21 2004-08-11 Sunesis Pharmaceuticals Inc Metodos para descubrir ligandos.
US20050084905A1 (en) 2002-03-21 2005-04-21 Prescott John C. Identification of kinase inhibitors
GB2388594A (en) 2002-05-16 2003-11-19 Bayer Ag Imidazo-triazine PDE 4 inhibitors
CA2494942A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
GB0303910D0 (en) 2003-02-20 2003-03-26 Merck Sharp & Dohme Therapeutic agents
WO2005000197A2 (en) 2003-04-11 2005-01-06 The Regents Of The University Of California Selective serine/threonine kinase inhibitors
US20050008640A1 (en) 2003-04-23 2005-01-13 Wendy Waegell Method of treating transplant rejection
EP1473039A1 (en) 2003-05-02 2004-11-03 Centre National De La Recherche Scientifique (Cnrs) Use of inhibitors and antisense oligonucleotides of BTK for the treatment of proliferative mastocytosis
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
US7393848B2 (en) 2003-06-30 2008-07-01 Cgi Pharmaceuticals, Inc. Certain heterocyclic substituted imidazo[1,2-A]pyrazin-8-ylamines and methods of inhibition of Bruton's tyrosine kinase by such compounds
SI1663217T1 (sl) * 2003-08-29 2010-10-29 Lifecycle Pharma As Trdne disperzije, ki vsebujejo takrolimus
US8131475B2 (en) 2003-09-03 2012-03-06 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods for identifying, diagnosing, and predicting survival of lymphomas
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
AU2004282219C1 (en) 2003-10-15 2009-12-17 Osi Pharmaceuticals, Inc. Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors
AU2003297904A1 (en) 2003-12-12 2005-07-14 University Of Maryland, Baltimore Immunomodulatory compounds that target and inhibit the py+3 binding site of tyrosene kinase p56 lck sh2 domain
BRPI0418031A (pt) 2003-12-22 2007-04-17 Gilead Sciences Inc inibidores de quinase fosfonato-substituìdos
US20050153990A1 (en) 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
EP1716151A1 (en) 2004-01-26 2006-11-02 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
EP1730148A4 (en) 2004-02-03 2009-08-19 Abbott Lab USE OF AMINOBENZOXAZOLES AS THERAPEUTIC AGENTS
ITMI20041314A1 (it) 2004-06-30 2004-09-30 Nuvera Fuel Cells Europ Srl Dispositivo di raffreddamento per celle a combustibili a membrana
AR053090A1 (es) 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
CA2582225A1 (en) 2004-09-28 2006-04-06 Mingde Xia Substituted dipiperdine ccr2 antagonists
CA2587192A1 (en) 2004-11-10 2006-05-18 Cgi Pharmaceuticals, Inc. Imidazo[1 , 2-a] pyrazin-8-ylamines useful as modulators of kinase activity
GB0425035D0 (en) 2004-11-12 2004-12-15 Novartis Ag Organic compounds
CN104688697A (zh) 2005-03-07 2015-06-10 拜尔健康护理有限责任公司 用于治疗癌症的包含ω-羧芳基取代的二苯基脲的药物组合物
MX2007011041A (es) 2005-03-10 2008-02-22 Cgi Pharmaceuticals Inc Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas.
ATE492545T1 (de) 2005-05-13 2011-01-15 Irm Llc Verbindungen und zusammensetzungen als proteinkinase-hemmer
EP1893612B1 (en) 2005-06-22 2011-08-03 Plexxikon, Inc. Pyrrolo [2, 3-b]pyridine derivatives as protein kinase inhibitors
US20070065449A1 (en) 2005-09-16 2007-03-22 Claire Verschraegen Method of treating cancer, especially soft tissue sarcoma utilizing gemcitabine in combination with docetaxel and anti-VEGF therapy (bevacizumab)
EP1957491A2 (en) 2005-11-12 2008-08-20 Boehringer Ingelheim International GmbH Pyrrolo (2,3-b) pyridine derivatives useful as tec kinase inhibitors
EP1981888A4 (en) 2006-01-13 2010-10-13 Pharmacyclics Inc TYROSINE KINASE INHIBITORS AND USES THEREOF
US20090317836A1 (en) 2006-01-30 2009-12-24 The Scripps Research Institute Methods for Detection of Circulating Tumor Cells and Methods of Diagnosis of Cancer in Mammalian Subject
EP2001498A4 (en) * 2006-03-20 2013-01-23 Vertex Pharma PHARMACEUTICAL COMPOSITIONS
US7585868B2 (en) 2006-04-04 2009-09-08 The Regents Of The University Of California Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists
EP2027087A2 (en) 2006-05-18 2009-02-25 MannKind Corporation Intracellular kinase inhibitors
DE102006026583A1 (de) 2006-06-07 2007-12-13 Bayer Healthcare Aktiengesellschaft Aryl-substituierte hetero-bicyclische Verbindungen und ihre Verwendung
EP2526933B1 (en) 2006-09-22 2015-02-25 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
ES2403546T3 (es) 2006-11-03 2013-05-20 Pharmacyclics, Inc. Sonda de actividad de la tirosina-cinasa de Bruton y procedimiento de utilización
NL2000640C2 (nl) 2007-03-05 2008-09-08 Stichting Wetsus Ct Of Excelle Werkwijze en systeem voor het zuiveren van een vloeistof.
US20120101114A1 (en) 2007-03-28 2012-04-26 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
SG10201508035TA (en) 2007-03-28 2015-10-29 Pharmacyclics Inc Inhibitors of bruton's tyrosine kinase
US20120065201A1 (en) 2007-03-28 2012-03-15 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
US20090010911A1 (en) 2007-04-06 2009-01-08 Iowa State University Research Foundation, Inc. Methods and compositions for affecting cyclophilin a regulation of kinases in modulating cellular activities
AU2008314632B2 (en) 2007-10-19 2015-05-28 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
EP2426109B1 (en) 2007-10-23 2013-12-18 F. Hoffmann-La Roche AG Novel kinase inhibitors
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
US20150152115A1 (en) 2007-12-27 2015-06-04 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
WO2009089494A2 (en) 2008-01-09 2009-07-16 Charleston Laboratories, Inc. Pharmaceutical compositions
JP2011518786A (ja) 2008-04-14 2011-06-30 アルデア バイオサイエンシズ，インコーポレイティド 調製及び使用のための組成物及び方法
EP2123626A1 (en) 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
EP3549934A1 (en) 2008-06-27 2019-10-09 Celgene CAR LLC Heteroaryl compounds and uses thereof
JP5369183B2 (ja) 2008-07-16 2013-12-18 ファーマサイクリックス，インク． 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤
ES2620442T3 (es) 2008-07-29 2017-06-28 Frontier Scientific, Inc. Uso de derivados de tetraquis(N-alquilpiridinio)-porfirina para la destrucción de microbios o la prevención de su crecimiento
US8426428B2 (en) 2008-12-05 2013-04-23 Principia Biopharma, Inc. EGFR kinase knockdown via electrophilically enhanced inhibitors
WO2010068806A1 (en) 2008-12-10 2010-06-17 Cgi Pharmaceuticals, Inc. Amide derivatives as btk inhibitors in the treatment of allergic, autoimmune and inflammatory disorders as well as cancer
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
NZ620174A (en) 2009-09-16 2016-08-26 Celgene Avilomics Res Inc Protein kinase conjugates and inhibitors
US7741330B1 (en) 2009-10-12 2010-06-22 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
AU2011260961B9 (en) 2010-05-31 2015-02-26 Ono Pharmaceutical Co., Ltd. Purinone derivative
US20120071497A1 (en) 2010-06-03 2012-03-22 Pharmacyclics, Inc. Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
DK2975042T3 (en) 2010-06-23 2019-01-21 Hanmi Science Co Ltd Novel fused pyrimidine derivatives to inhibit tyrosine kinase activity
BR112013003388A2 (pt) 2010-08-10 2016-07-12 Celgene Avilomics Res Inc sal de besilato de um inibidor de btk
US8541391B2 (en) 2010-10-28 2013-09-24 Viropharma Incorporated Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-β-L-ribofuranosyl-1H-benzimidazole
US8501484B2 (en) 2011-03-14 2013-08-06 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
EP2710005B1 (en) 2011-05-17 2016-10-05 Principia Biopharma Inc. Tyrosine kinase inhibitors
BR112014001440A2 (pt) 2011-07-18 2017-02-21 Tokai Pharmaceuticals Inc novas composições e métodos para o tratamento de câncer de próstata
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
DK3181122T3 (da) * 2012-01-13 2023-06-06 Xspray Pharma Ab Publ Farmaceutisk dasatinib-sammensætning
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
JP5514256B2 (ja) 2012-05-18 2014-06-04 株式会社東芝 磁気記憶素子及びその製造方法
US9296753B2 (en) 2012-06-04 2016-03-29 Pharmacyclics Llc Crystalline forms of a Bruton's tyrosine kinase inhibitor
KR102150432B1 (ko) 2012-06-18 2020-09-01 프린시피아 바이오파마, 인코퍼레이티드 암 및 자가면역 질환 치료에 유용한 가역적인 공유 피롤로- 또는 피라졸로피리미딘
WO2014004707A1 (en) 2012-06-29 2014-01-03 Principia Biopharma Inc. Formulations comprising ibrutinib
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CN103121999A (zh) 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
CN104854107A (zh) 2012-11-15 2015-08-19 药品循环公司 作为激酶抑制剂的吡咯并嘧啶化合物
EP3811974A1 (en) 2013-05-30 2021-04-28 Infinity Pharmaceuticals, Inc. Treatment of cancers using pi3 kinase isoform modulators
US20160067241A1 (en) 2013-06-13 2016-03-10 Dennis M. Brown Compositions and methods to improve the therapeutic benefit of suboptimally administered chemical compounds including substituted naphthalimides such as amonafide for the treatment of immunological, metabolic, infectious, and benign or neoplastic hyperproliferative disease conditions
EP3027192A4 (en) 2013-08-02 2017-03-22 Pharmacyclics, LLC Methods for the treatment of solid tumors
US10253244B2 (en) 2013-09-04 2019-04-09 Halliburton Energy Services, Inc. Scale-inhibiting cocrystals for treatment of a subterranean formation
CA2922398C (en) 2013-09-12 2023-08-29 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
JP6508785B2 (ja) 2013-10-25 2019-05-08 ファーマサイクリックス エルエルシー ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置
WO2015071432A1 (en) 2013-11-14 2015-05-21 Sandoz Ag Pharmaceutical compositions of ibrutinib
CN103694241A (zh) 2013-11-27 2014-04-02 苏州晶云药物科技有限公司 Pci-32765的新晶型a及其制备方法
US20160310417A1 (en) 2013-12-20 2016-10-27 Emory University Formulations and Methods For Targeted Ocular Delivery of Therapeutic Agents
CN106008516A (zh) 2014-01-29 2016-10-12 苏州晶云药物科技有限公司 依鲁替尼的新晶型及其制备方法
EA201691582A1 (ru) 2014-02-07 2017-01-30 Оспекс Фармасьютикалз, Инк. Новые фармацевтические препараты
WO2015123654A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
US20150267752A1 (en) 2014-03-19 2015-09-24 Roller Bearing Company Of America, Inc. Bearing outer race having a radially inwardly biased seal
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
AU2015237744A1 (en) 2014-03-27 2016-09-15 Wavelength Enterprises Ltd Ibrutinib solid forms and production process therefor
CN105085529A (zh) 2014-05-15 2015-11-25 广东东阳光药业有限公司 依鲁替尼新晶型及其制备方法
US9127069B1 (en) 2014-06-11 2015-09-08 Antecip Bioventures LLC Compositions comprising rank/rankl antagonists and related compounds for treating pain
US20150110871A1 (en) 2014-06-02 2015-04-23 David Wong Gastric retentive tablet compositions
US20160008777A1 (en) 2014-07-09 2016-01-14 Novotec Consulting Inc. Pharmaceutical compounding kit
PT107846B (pt) 2014-08-01 2019-03-22 Hovione Farm S A Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada
WO2016020697A1 (en) 2014-08-06 2016-02-11 Cipla Limited Pharmaceutical compositions of polymeric nanoparticles
WO2016022942A1 (en) * 2014-08-07 2016-02-11 Pharmacyclics Llc Novel formulations of a bruton's tyrosine kinase inhibitor
EP3180343A1 (en) 2014-08-14 2017-06-21 Assia Chemical Industries Ltd. Solid state forms of ibrutinib
ES2727952T3 (es) 2014-10-01 2019-10-21 Ratiopharm Gmbh Sal de adición de ácido de ibrutinib
CN104523695A (zh) 2014-11-12 2015-04-22 广东东阳光药业有限公司 一种治疗过度增生性疾病的药物组合物
CN105640961A (zh) 2014-11-18 2016-06-08 山东瑞禾医药科技有限公司 一种含依鲁替尼的药物组合物
WO2016079216A1 (en) 2014-11-20 2016-05-26 Sandoz Ag Physical forms of ibrutinib, a bruton's kinase inhibitor
US20150224060A1 (en) 2015-01-03 2015-08-13 David Wong Gastric retentive tablet compositions
CZ201584A3 (cs) 2015-02-09 2016-08-17 Zentiva, K.S. Sůl Ibrutinib sulfátu
SG11201707122QA (en) * 2015-03-03 2017-09-28 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibtor
WO2016139588A1 (en) 2015-03-03 2016-09-09 Dr. Reddy's Laboratories Limited Polymorphs of ibrutinib
EP3277688B1 (en) 2015-04-02 2019-05-08 ratiopharm GmbH Co-crystals of ibrutinib
EP3280446A1 (en) 2015-04-06 2018-02-14 Janssen Pharmaceutica, N.V. Compositions containing ibrutinib
CN105294696A (zh) 2015-11-19 2016-02-03 上海创诺医药集团有限公司 依鲁替尼新晶型及其制备方法
CN105440040B (zh) 2015-12-23 2018-03-13 浙江京新药业股份有限公司 依鲁替尼的纯化方法
CN105646484A (zh) 2016-03-01 2016-06-08 孙霖 晶型b及制备方法
CN105646498A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型f及制备方法
CN105646499A (zh) 2016-03-01 2016-06-08 孙霖 依鲁替尼晶型g及制备方法
CN106619643A (zh) 2016-11-11 2017-05-10 上海雅本化学有限公司 一种含依鲁替尼的药物组合物

Also Published As

Publication number Publication date
US9545407B2 (en) 2017-01-17
EP3193877A4 (en) 2018-04-04
EP3193877A1 (en) 2017-07-26
BR112017002231A2 (pt) 2018-07-17
MX2017001671A (es) 2017-07-04
US20190282578A1 (en) 2019-09-19
US20160038496A1 (en) 2016-02-11
IL250085A0 (en) 2017-03-30
CN106573002A (zh) 2017-04-19
KR20170033358A (ko) 2017-03-24
CA2955747A1 (en) 2016-02-11
RU2017106795A (ru) 2018-09-07
US20170079981A1 (en) 2017-03-23
RU2017106795A3 (ko) 2019-04-12
AU2015300798A1 (en) 2017-02-02
US20180028537A1 (en) 2018-02-01
JP2017523206A (ja) 2017-08-17
WO2016022942A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
IL250085A0 (en) New compounds of proton tyrosine kinase inhibitor
ZA201907661B (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
HK1256857A1 (zh) 多氟化合物作為布魯頓酪氨酸激酶抑制劑
IL274716A (en) Synthesis of a proton tyrosine kinase inhibitor
IL255831A (en) Inhibitors of bruton's tyrosine kinase
HK1249736A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的共結晶體
EP3141546A4 (en) Inhibitor of bruton's tyrosine kinase
EP3174539A4 (en) Inhibitors of bruton's tyrosine kinase
EP3414234A4 (en) BRUTON TYROSINE KINASE HEMMER
IL244492A0 (en) Broton tyrosine kinase inhibitors
ZA201805439B (en) Bruton's tyrosine kinase inhibitors
EP3177366A4 (en) Bruton's tyrosine kinase inhibitor combinations and uses thereof
EP3159340A4 (en) New bruton's tyrosine kinase inhibitor
HK1249737A1 (zh) 布魯頓氏酪氨酸激酶抑制劑的溶劑化形式
IL259863B (en) Polycyclic compounds as inhibitors of proton tyrosine kinase
ZA201903694B (en) Inhibitors of bruton's tyrosine kinase
ZA201906887B (en) Bruton's tyrosine kinase inhibitors
HK1243929A1 (zh) Tlr抑制劑和布魯頓酪氨酸激酶抑制劑組合